Previous 10 | Next 10 |
2023-08-17 18:21:38 ET More on Kodiak Sciences Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape Kodiak cut to Neutral at UBS as lead asset dropped from trials Biggest stock movers today: Nikola, AMC Entertainment, POSCO Holdings and more ...
2023-08-14 17:03:53 ET Kodiak Sciences press release ( NASDAQ: KOD ): Q2 GAAP EPS of -$1.53. Kodiak ended the second quarter of 2023 with $378.7 million of cash and cash equivalents. For further details see: Kodiak Sciences GAAP EPS of -$1.53
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and c...
(NewsDirect) Kodal Minerals PLC (AIM:KOD) chief executive Bernard Aylward speaks to Thomas Warner from Proactive after the mineral exploration and development company announced the prepayment of US$3.5mln from the Hainan Group as part of the funding package for the Bougouni Lithium Projec...
2023-07-27 14:33:09 ET More on Kodiak Sciences Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape Kodiak gains as late-stage trial for eye disease candidate meets key goal Kodiak cut to Sell at Citi on potential setback to lead asset in August ...
ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws. On July 24, 2023, Kodiak released top line results from sever...
NEW YORK, NY / ACCESSWIRE / July 26, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kodiak Sciences Inc. ("Kodiak" or "the Company") (NASDAQ:KOD). Investors who purchased Kodiak securities are encouraged to obtain additional information...
2023-07-25 08:22:48 ET NeuroOne Medical Technologies Corporation ( NMTC ) -35% . announces pricing of public offering of common stock . Stoke Therapeutics ( STOK ) -34% announces positive new safety & efficacy data from patients treated with STK-001 in the ...
2023-07-24 10:09:58 ET Gainers: Armata Pharmaceuticals ( ARMP ) +19% . Janux Therapeutics ( JANX ) +11% . Amylyx Pharmaceuticals ( AMLX ) +8% . Coherus BioSciences ( CHRS ) +7% . Nuwellis ( NUWE ) +7% . Losers: Kodiak...
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program PR Newswire PALO ALTO, Calif. , July 24, 2023 ...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...